Moderate Hepatic Impairment
10
2
2
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
38%
3 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (10)
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
Pharmacokinetics of KBP-5074 in Patients With Moderate Hepatic Impairment
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
A Study of Belzutifan (MK-6482) in Participants With Hepatic Impairment (MK-6482-020)
A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction
A Pharmacokinetic Study of Mitapivat in Participants With Moderate Hepatic Impairment Compared to Matched Healthy Control Participants With Normal Hepatic Function
Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients
Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants
A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
A Study of TMC207 in Patients With Moderately Impaired Hepatic Function